In this study, we aim to explore the potential of mRNA vaccine technology for the development of a subunit vaccine against ASFV. For this pilot project, we focused on assessing the immunogenicity of...
PRRS modified live virus (MLV) vaccines have been licensed for clinical administration for over 20 years. The vaccines confer solid protection against homologous PRRSV strains. However, the extent...
PRRS modified live virus (MLV) vaccines have been licensed for clinical administration for over 20 years. The vaccines confer solid protection against homologous PRRSV strains. However, the extent...
Current PRRS vaccines are not adequately effective for control and eradication of PRRS. The main limitation of the current PRRS vaccines is their sub-optimal coverage against divergent PRRSV strains...